Government Announces Extra Support to Tackle Post-Pandemic School Speech Therapy Backlog
The government will send more specialists to primary schools to help clear the backlog of children waiting for speech and language support, which has grown since the COVID-19 pandemic.
Announcing the plans on Friday, the Department for Education (DfE) said the measures would support up to 20,000 more children.
The Early Language Support for Every Child (ELSEC) programme deploys specialist teams to help identify and support children with language and communication needs.
Since its launch in 2023, ELSEC has supported some 200 early years settings and primary schools, trained just over 3,000 staff, and provided support to 20,000 children.
The department said that developmental delays 'have been a growing issue since the pandemic,' with more than 40,000 children waiting over 12 weeks for speech and language therapy.
SEND Children
The DfE said these delays are particularly prevalent for children with special education needs and disability (SEND).
The number of children with SEND has increased from 1.3 million in 2020 to 1.67 million in 2024; one in four of these require additional support to help them with speaking, listening, and comprehension.
Related Stories
5/22/2025
4/17/2025
Those requiring specialist support and on Educational Heath Care Plans have also increased, from 250,000 in 2015 to 575,000 in 2024.
Minister for school standards Catherine McKinnell said that unless speech and language delays are spotted early, they can have an impact on children's attainment, socialisation abilities, attendance, and future life chances.
She said: 'ELSEC is turning this around for so many pupils—and particularly those with SEND—helping them find their voice and thrive at school and with their friends and family.
'This type of approach is exactly what we want to see in a reformed SEND system that delivers the support children need at the earliest stage and restores parents' trust in a system which has let them down for too long.'
Impact of Lockdowns
The government's acknowledgment that developmental delays have become a growing issue since 2020 echoes other reports that have highlighted similar concerns in the aftermath of the pandemic.
In March 2024, the Office for National Statistics said the number of years of good health that newborn babies in England and Wales can expect to enjoy has fallen over the past decade, with the lingering impact of 'the pandemic' having contributed to the decline.
However, critics said at the time that it was 'disingenuous' of a public body not to identify lockdowns and other restrictions as the culprits, rather than the COVID-19 virus.
Molly Kingsley of children's rights group Us For Them, had
'We know there have been multiple studies done into the effects on speech and language development of babies and young children and we know that had nothing to do with the virus and everything to do with the restrictions—the masks and so on.'
Children Not Ready for School
Another report
The report placed some blame on the pandemic for exacerbating early years developmental problems.
Undated photo of a child playing with plastic building blocks
PA
It said that nurseries and primary schools were highly concerned around speech and language, with a significant number of children below age-related targets by the end of reception year, when children are typically 4 to 5 years old.
Authors had warned that a 'widened' language gap between children from more and less advantaged communities had developed since the COVID-19 era, which could lead to an even greater attainment gap over time.
Suspensions
The pandemic has also been cited as a contributing factor to the decline in pupil behaviour in schools.
Government data
This is 93 percent higher than in the spring of 2019—the last school year before lockdowns—when there were 153,465 suspensions.
Paul Whiteman, general secretary at school leaders' union NAHT, said at the time that poor behaviour leading to suspensions and exclusions 'often has causes outside the classroom, with big challenges facing children and families, including poverty, the cost-of-living crisis, accessing wider services for Send support, and some lingering impact of the pandemic.'
Rachel Roberts contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
How AI could help stop the next pandemic before it starts
Could artificial intelligence tools be used to stop the next pandemic before it starts? During the Covid pandemic, new technology developed by researchers at Johns Hopkins and Duke universities didn't exist. But, for the first time, researchers there say they've devised a revolutionary large language modeling tool - the type of generative AI used in ChatGP - to help predict the spread of any infectious disease, such as bird flu, monkeypox, and RSV. That could help save lives and reduce infections. 'Covid-19 elucidated the challenge of predicting disease spread due to the interplay of complex factors that were constantly changing,' Johns Hopkins' Lauren Gardner, a modeling expert who created the Covid dashboard that was relied upon by people worldwide during the pandemic, said in a statement. 'When conditions were stable the models were fine. However, when new variants emerged or policies changed, we were terrible at predicting the outcomes because we didn't have the modeling capabilities to include critical types of information,' she added. 'The new tool fills this gap.' Gardner was one of the authors of the study published Thursday in the Nature Computational Science journal. The tool, named PandemicLLM, considers recent infection spikes, new variants, and stringent protective measures. The researchers utilized data that had never been used before in pandemic prediction tools, finding that PandemicLLM could accurately predict disease patterns and hospitalization trends one to three weeks out. The data included rates of cases hospitalizations and vaccines, types of government policies, characteristics of disease variants and their prevalence, and state-level demographics. The model incorporates these elements to predict how they will come together and affect how disease behaves. They retroactively applied PandemicLLM to the Covid pandemic, looking at each state over the course of 19 months. The authors said the tool was particularly successful when the outbreak was in flux. It also outperformed existing state-of-the-art forecasting methods, including the highest performing ones on the Centers for Disease Control and Prevention's CovidHub. 'Traditionally we use the past to predict the future,' author Hao 'Frank' Yang, a Johns Hopkins assistant professor of civil and systems engineering, said. 'But that doesn't give the model sufficient information to understand and predict what's happening. Instead, this framework uses new types of real-time information.' Going forward, they are looking at how large language models can replicate the ways individuals make decisions about their health. They hope that such a model would help officials to design safer and more effective policies. More than a million Americans have died from Covid. It's not a matter of if there will be a next pandemic, but when. Right now, the U.S. is dealing with the spread of H5N1 bird flu, RSV, HMPV, pertussis, and measles, among other health concerns. Vaccination rates for measles have plunged since the pandemic, and general vaccine hesitancy has increased. That has resulted in fears that the nation could see decades of health progress reversed. Furthermore, U.S. health officials have acted to separate from global efforts to respond to pandemics, withdrawing from the World Health Organization earlier this year. Last month, they limited access to Covid vaccines for certain groups. 'We know from Covid-19 that we need better tools so that we can inform more effective policies,' Gardner said. 'There will be another pandemic, and these types of frameworks will be crucial for supporting public health response.'
Yahoo
32 minutes ago
- Yahoo
GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy
PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. MISSISSAUGA, ON, June 6, 2025 /CNW/ - GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country. Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap. Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies. "As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges," said Michelle Horn, Country Medical Director, GSK Canada. "Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred." Transforming Immunization Through Pharmacy Innovation The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include: Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations Leveraging digital health tools and technology to support clinical decision-making and personalized outreach Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services Implementing science methodologies to ensure successful and scalable solutions across regions and populations This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies. "As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries," said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. "PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally." Impact Beyond the Lab In addition to funding innovative research, GSK's investment will also: Provide funding to support new interdisciplinary projects with direct policy and practice implications Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention Establish a network of community pharmacies engaged in research, data collection and pilot projects Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public Strategic Alignment with Public Health and Policy This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development. "Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare," added Michelle Horn, Country Medical Director, GSK Canada. "We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health." Why Waterloo and Why Now? The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application. PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation. About the University of Waterloo School of PharmacyThe School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes. About GSK GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025. SOURCE GlaxoSmithKline Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
In axing mRNA contract, Trump delivers another blow to US biosecurity, former officials say
This is a KFF Health News story. The Trump administration's cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu viruses is the latest blow to national defense, former health security officials said. They warned that the U.S. could be at the mercy of other countries in the next pandemic. "The administration's actions are gutting our deterrence from biological threats," said Beth Cameron, a senior adviser to the Brown University Pandemic Center and a former director at the White House National Security Council. "Canceling this investment is a signal that we are changing our posture on pandemic preparedness," she added, "and that is not good for the American people." Flu pandemics killed up to 103 million people worldwide last century, researchers estimate. MORE: Bird flu is continuing to spread in animals across the US. Here's what you need to know In anticipation of the next big one, the U.S. government began bolstering the nation's pandemic flu defenses during the George W. Bush administration. These strategies were designed by the security council and the Biomedical Advanced Research and Development Authority at the Department of Health and Human Services, among other agencies. The plans rely on rolling out vaccines rapidly in a pandemic. Moving fast hinges on producing vaccines domestically, ensuring their safety and getting them into arms across the nation through the public health system. The Trump administration is undermining each of these steps as it guts health agencies, cuts research and health budgets and issues perplexing policy changes, health security experts said. Since President Donald Trump took office, at least half of the security council's staff have been laid off or left, and the future of BARDA is murky. The nation's top vaccine adviser, Peter Marks, resigned under pressure in March, citing "the unprecedented assault on scientific truth." Most recently, Trump's clawback of funds for mRNA vaccine development put Americans on shakier ground in the next pandemic. "When the need hits and we aren't ready, no other country will come to our rescue and we will suffer greatly," said Rick Bright, an immunologist and a former BARDA director. Countries that produced their own vaccines in the COVID-19 pandemic had first dibs on the shots. While the United States, home to Moderna and Pfizer, rolled out second doses of mRNA vaccines in 2021, hundreds of thousands of people in countries that didn't manufacture vaccines died waiting for them. The most pertinent pandemic threat today is the bird flu virus H5N1. Researchers around the world were alarmed when it began spreading among cattle in the U.S. last year. Cows are closer to humans biologically than birds, indicating that the virus had evolved to thrive in cells like our own. As hundreds of herds and dozens of people were infected in the U.S., the Biden administration funded Moderna to develop bird flu vaccines using mRNA technology. As part of the agreement, the U.S. government stipulated it could purchase doses in advance of a pandemic. That no longer stands. Researchers can make bird flu vaccines in other ways, but mRNA vaccines are developed much more quickly because they don't rely on finicky biological processes, such as growing elements of vaccines in chicken eggs or cells kept alive in laboratory tanks. Time matters because flu viruses mutate constantly, and vaccines work better when they match whatever variant is circulating. MORE: 2nd bird flu virus detected in western US. What does this mean for prevention? Developing vaccines within eggs or cells can take 10 months after the genetic sequence of a variant is known, Bright said. And relying on eggs presents an additional risk when it comes to bird flu because a pandemic could wipe out billions of chickens, crashing egg supplies. Decades-old methods that rely on inactivated flu viruses are riskier for researchers and time-consuming. Still the Trump administration invested $500 million into this approach, which was largely abandoned by the 1980s after it caused seizures in children. "This politicized regression is baffling," Bright said. A bird flu pandemic may begin quietly in the U.S. if the virus evolves to spread between people but no one is tested at first. Indeed, the Centers for Disease Control and Prevention's dashboard suggests that only 10 farmworkers have been tested for the bird flu since March. Because of their close contact with cattle and poultry, farmworkers are at highest risk of infection. As with many diseases, only a fraction of people with the bird flu become severely sick. So the first sign that the virus is widespread might be a surge in hospital cases. "We'd need to immediately make vaccines," said Angela Rasmussen, a virologist at the University of Saskatchewan in Canada. The U.S. government could scale up production of existing bird flu vaccines developed in eggs or cells. However, these vaccines target an older strain of H5N1 and their efficacy against the virus circulating now is unknown. In addition to the months it takes to develop an updated version within eggs or cells, Rasmussen questioned the ability of the government to rapidly test and license updated shots, with a quarter of HHS staff gone. If the Senate approves Trump's proposed budget, the agency faces about $32 billion in cuts. Further, the Trump administration's cuts to biomedical research and its push to slash grant money for overhead costs could undermine academic hospitals, rendering them unable to conduct large clinical trials. And its cuts to the CDC and to public health funds to states mean that fewer health officials will be available in an emergency. "You can't just turn this all back on," Rasmussen said. "The longer it takes to respond, the more people die." Researchers suggest other countries would produce bird flu vaccines first. "The U.S. may be on the receiving end like India was, where everyone -- rich people, too -- got vaccines late," said Achal Prabhala, a public health researcher in India at medicines access group AccessIBSA. He sits on the board of a World Health Organization initiative to improve access to mRNA vaccines in the next pandemic. A member of the initiative, the company Sinergium Biotech in Argentina, is testing an mRNA vaccine against the bird flu. If it works, Sinergium will share the intellectual property behind the vaccine with about a dozen other groups in the program from middle-income countries so they can produce it. MORE: 12 months and 70 cases since the first human bird flu infection: Are we any safer? The Coalition for Epidemic Preparedness Innovations, an international partnership headquartered in Norway, is providing funds to research groups developing rapid-response vaccine technology, including mRNA, in South Korea, Singapore and France. And CEPI committed up to $20 million to efforts to prepare for a bird flu pandemic. This year, the Indian government issued a call for grant applications to develop mRNA vaccines for the bird flu, warning it "poses a grave public health risk." Pharmaceutical companies are investing in mRNA vaccines for the bird flu as well. However, Prabhala says private capital isn't sufficient to bring early-stage vaccines through clinical trials and large-scale manufacturing. That's because there's no market for bird flu vaccines until a pandemic hits. Limited supplies means the United States would have to wait in line for mRNA vaccines made abroad. States and cities may compete against one another for deals with outside governments and companies, like they did for medical equipment at the peak of the covid pandemic. "I fear we will once again see the kind of hunger games we saw in 2020," Cameron said. In an email response to queries, HHS communications director Andrew Nixon said, "We concluded that continued investment in Moderna's H5N1 mRNA vaccine was not scientifically or ethically justifiable." He added, "The decision reflects broader concerns about the use of mRNA platforms -- particularly in light of mounting evidence of adverse events associated with COVID-19 mRNA vaccines." Nixon did not back up the claim by citing analyses published in scientific journals. In dozens of published studies, researchers have found that mRNA vaccines against COVID are safe. For example, a placebo-controlled trial of more than 30,000 people in the U.S. found that adverse effects of Moderna's vaccine were rare and transient, whereas 30 participants in the placebo group suffered severe cases of COVID and one died. More recently, a study revealed that three of nearly 20,000 people who got Moderna's vaccines and booster had significant adverse effects related to the vaccine, which resolved within a few months. COVID, on the other hand, killed four people during the course of the study. As for concerns about the heart issue, myocarditis, a study of 2.5 million people who got at least one dose of Pfizer's mRNA vaccine revealed about two cases per 100,000 people. COVID causes 10 to 105 myocarditis cases per 100,000. Nonetheless, HHS Secretary Robert F. Kennedy Jr., who founded an anti-vaccine organization, has falsely called COVID shots "the deadliest vaccine ever made." And without providing evidence, he said the 1918 flu pandemic "came from vaccine research." Politicized mistrust in vaccines has grown. Far more Republicans said they trust Kennedy to provide reliable information on vaccines than their local health department or the CDC in a recent KFF poll: 73% versus about half. Should the bird flu become a pandemic in the next few years, Rasmussen said, "we will be screwed on multiple levels." In axing mRNA contract, Trump delivers another blow to US biosecurity, former officials say originally appeared on
